Literature DB >> 476756

Electrophysiological effects of ethmozin on canine myocardium.

R Ruffy, L V Rozenshtraukh, V Elharrar, D P Zipes.   

Abstract

The electrophysiological effects of ethmozin on canine myocardium were studied in anesthetised open-chest animals and in superfused Purkinje fibres. The drug did not change spontaneous sinus node cycle length and atrioventricular conduction time when selectively injected into the sinus nodal artery and into the posterior septal artery, respectively. Right and left ventricular diastolic excitability threshold and refractory period were increased following the intravenous administration of ethmozin, 4 mg/kg-1. Ethmozin (3 to 5 mg/kg-1 i.v.) markedly increased conduction delay in the ischaemic zone of the left ventricle during acute coronary artery occlusion. This change was associated with the development of ventricular fibrillation in 50% of the dogs. In vitro, ethmozin 1 X 10(-3) and 1 X 10(-2) g.litre-1 shortened Purkinje fibres' action potential duration. At 1 X 10(-2) g.litre-1, ethmozin decreased the rate of rise of phase 0, and slightly reduced action potential amplitude.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 476756     DOI: 10.1093/cvr/13.6.354

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  3 in total

1.  Use-dependent block of Ca2+ current by moricizine in guinea-pig ventricular myocytes: a possible ionic mechanism of action potential shortening.

Authors:  T Yamane; A Sunami; T Sawanobori; M Hiraoka
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

Review 2.  Moricizine. A review of its pharmacological properties, and therapeutic efficacy in cardiac arrhythmias.

Authors:  A Fitton; M T Buckley
Journal:  Drugs       Date:  1990-07       Impact factor: 9.546

3.  Electrophysiological effects of Ro 22-9194, a new antiarrhythmic agent, on guinea-pig ventricular cells.

Authors:  K Maruyama; I Kodama; T Anno; R Suzuki; J Toyama
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.